Modulation of adipocytokines production and serum NEFA level by metformin, glimepiride, and sitagliptin in HFD/STZ diabetic rats

Biochemistry Research International

Volumn 2015, Issue , 2015, Pages

  Saad, Mohamed I ^a   Kamel, Maher A ^a   Hanafi, Mervat Y ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

RATTUS;

EID: 84925433207     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2015/138134     Document Type: Article

References (24)

1. Y. Lin and Z. Sun, "Current views on type 2 diabetes, " Journal of Endocrinology, vol. 204, no. 1, pp. 1-11, 2010.
2. L. Chen, D. J. Magliano, and P. Z. Zimmet, "The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives, " Nature Reviews Endocrinology, vol. 8, no. 4, pp. 228-236, 2011.
3. C. J. Nolan, P. Damm, and M. Prentki, "Type 2 diabetes across generations: Frompathophysiology to prevention and management, " The Lancet, vol. 378, no. 9786, pp. 169-181, 2011.
4. M. Bluher, "Adipokines-removing road blocks to obesity and diabetes therapy, " Molecular Metabolism, vol. 3, no. 3, pp. 230-240, 2014.
5. T. Romacho, M. Elsen, D. Rohrborn, and J. Eckel, "Adipose tissue and its role in organ crosstalk, " Acta Physiologica, vol. 210, no. 4, pp. 733-753, 2014.
6. S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, "Adipose tissue: the new endocrine organ? A review article, " Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847-1856, 2009.
7. K. Rabe, M. Lehrke, K. G. Parhofer, and U. C. Broedl, "Adipokines and insulin resistance, "MolecularMedicine, vol. 14, no. 11-12, pp. 741-751, 2008.
8. L. Zabeau, D. Lavens, F. Peelman, S. Eyckerman, J. Vandekerckhove, and J. Tavernier, "The ins and outs of leptin receptor activation, " FEBS Letters, vol. 546, no. 1, pp. 45-50, 2003.
9. D. M. Muoio and C. B. Newgard, "Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes, " Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 193-205, 2008.
10. M. I. Saad, M. A. Kamel, M. Y. Hanafi, M. H. Helmy, and R. R. Shehata, "Effect of sitagliptin and glimepiride on glucose homeostasis and cAMP levels in peripheral tissues of HFD/STZ diabetic rats, "TheAmerican Journal of Biomedical Research, vol. 2, no. 3, pp. 52-60, 2014.
11. B. Mlinar, J. Marc, A. Janez, and M. Pfeifer, "Molecular mechanisms of insulin resistance and associated diseases, " Clinica Chimica Acta, vol. 375, no. 1-2, pp. 20-35, 2007.
12. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, "Cellular and molecular mechanisms of metformin: an overview, " Clinical Science, vol. 122, no. 6, pp. 253-270, 2012.
13. M. K. Piya, A. A. Tahrani, and A. H. Barnett, "Emerging treatment options for type 2 diabetes, " British Journal of Clinical Pharmacology, vol. 70, no. 5, pp. 631-644, 2010.
14. E. Phielix, A. Brehm, E. Bernroider et al. , "Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes, " Diabetes, Obesity and Metabolism, vol. 15, no. 10, pp. 915-922, 2013.
15. D. J. Drucker andM. A. Nauck, "The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, " The Lancet, vol. 368, no. 9548, pp. 1696-1705, 2006.
16. S. E. Kahn, M. E. Cooper, and S. Del Prato, "Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future, " The Lancet, vol. 383, no. 9922, pp. 1068-1083, 2014.
17. A. D. Mooradian, "Dyslipidemia in type 2 diabetes mellitus, " Nature Clinical Practice Endocrinology andMetabolism, vol. 5, no. 3, pp. 150-159, 2009.
18. G. Anfossi, I. Russo, K. Bonomo, and M. Trovati, "The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetesmellitus, " Current Vascular Pharmacology, vol. 8, no. 3, pp. 327-337, 2010.
19. D. Addison and D. Aguilar, "Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies, " Current Atherosclerosis Reports, vol. 13, no. 2, pp. 115-122, 2011.
20. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, "Adipokines in inflammation andmetabolic disease, "Nature Reviews Immunology, vol. 11, no. 2, pp. 85-97, 2011.
21. S. A. Ritchie, M.-A. Ewart, C. G. Perry, J. M. C. Connell, and I. P. Salt, "The role of insulin and the adipocytokines in regulation of vascular endothelial function, " Clinical Science, vol. 107, no. 6, pp. 519-532, 2004.
22. Y. W. Kim, J. Y. Kim, Y. H. Park et al. , "Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance, " Diabetes, vol. 55, no. 3, pp. 716-724, 2006.
23. R. S. Hundal and S. E. Inzucchi, "Metformin, " Drugs, vol. 63, no. 18, pp. 1879-1894, 2003.
24. G. P. Fadini and A. Avogaro, "Dipeptidyl peptidase-4 inhibition and vascular repair bymobilization of endogenous stemcells in diabetes and beyond, " Atherosclerosis, vol. 229, no. 1, pp. 23-29, 2013.